The PennZone

  • Home
  • Books
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Business
  • Artificial Intelligence
  • Health

Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
The PennZone/10278266

Trending...
  • Regional Magazines Shine at IRMA Awards
  • Perfexion Inc. Recognized in the Philadelphia Business Journal's 2026 Branding, Marketing and Media Services List
  • Birch Run Psychological Services Launches Updated Online Therapy Website
Actuated Medical Inc.
BELLEFONTE, Pa. - PennZone -- Treating alcohol misuse remains a major challenge worldwide.  Given the diverse biological processes that contribute to alcohol use disorder, new medications are needed to provide a broader spectrum of treatment options. Some people may respond to a medication that helps with craving, others may respond to a medication that relieves impulsivity, others may respond to a medication that reverses the negative emotional state of withdrawal or protracted withdrawal. Just like any other medical condition, people with alcohol use disorder deserve to have a range of treatment options available to them. Scientists are working to develop a larger menu of pharmaceutical treatments that could be tailored to individual needs.

Actuated Medical's innovative NeuralGlider Injector will enable the delivery of next-generation medications into small targets deep in the brain, to fundamentally change the trajectory of alcohol use disorder and improve outcomes.  The goal is to deliver a therapeutic that will damp down cravings enough for other therapies to have a chance to work.  The therapeutic gets delivered accurately to the target and stays there.

Actuated Medical, Inc. has been awarded a $3 million pre-clinical Phase II Small Business Innovative Research (SBIR) grant from the National Institutes of Health-National Institute on Alcohol Abuse and Alcoholism to develop the "Oscillated Insertion Tool for Minimally Invasive, Low-Damage, Accurate Placement of Delivery Cannula to Improve Efficacy for DREADDS (designer receptors exclusively activated by designer drugs) Therapy in Alcohol Addiction Treatment" which will be commercially recognized as the NeuralGlider Injector.

More on The PennZone
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago

"Many of us know someone who is dealing with an alcohol addiction and have felt helpless as we watched them suffer. That is why we are so excited to develop and commercialize our NeuralGlider Injector technology as it may one day help to offer a more effective treatment option for those afflicted with alcohol use disorder." Maureen L. Mulvihill, Ph.D., Actuated Medical President, CEO, & Co-Founder.

About Actuated Medical, Inc.

Actuated Medical is a Pennsylvania medical device product innovator founded in 2006 on the entrepreneurial idea that electronically controlled motion can solve clinical needs and improve patient outcomes. They are developing products in the areas of neuroscience, critical care, gastroenterology, and pediatrics. Their Actuated Neuroscience Division focuses on developing tools to assist researchers in understanding neurological conditions. Recently, they were awarded a 5-year Contract under the National Institutes of Health (NIH) Blueprint MedTech (BPMT) initiative to assist brain researchers conduct their FDA compliant testing. Actuated has 42 issued patents and 7 FDA 510(k) clearances. They have been the recipient of a 2014 & 2020 SBA Tibbets Awards for SBIR commercialization excellence. Actuated's CEO was the 2020 Life Sciences Pennsylvania CEO of the Year due to the teams Covid PPE pivot.

More on The PennZone
  • Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
  • Affordable Braces in Allentown Made Accessible Through Exeter Smiles' Flexible Payment Options
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
  • Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
  • Perfexion Inc. Named to the Philadelphia Business Journal's 2026 List of Largest Tech Employers

More information about Actuated neural device innovations.

See www.actuatedneuroscience.com

NIH Disclaimer.

Research reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes of Health under Award Number R44AA030512. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

###

For more information about this topic, please contact Maureen L. Mulvihill, Ph.D. by phone at 814-355-0003 or email at info@actuatedmedical.com.

Additional information can be found by visiting:

https://actuatedmedical.com

https://actuatedneuroscience.com

Contact
Actuated Medical
***@actuatedmedical.com


Source: Actuated Medical, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
  • Keystone Consulting Engineers Expands into Brodheadsville, Strengthening Regional Engineering
  • Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
  • Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
  • Visit London Appoints The SEO Works for AI-First Search Strategy
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
  • YWCA Hanover to Host 7th Annual EMERGE Women's Conference
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Is Your Home Buyer REALLY Qualified?
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
  • NYC Big Book Award Celebrates 10th Anniversary with Announcement of 2026 Winners
  • Birch Run Psychological Services Launches Updated Online Therapy Website

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 233
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 206
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 201
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 181
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 156
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 149
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 137
  • Brévant Guide Launches New National Restaurant Guide Across Canada - 124
  • Calling all healthcare process experts: Share your ideas at #HSPI2027 in Orlando - 119
  • VC Fast Pitch and Steamwork Ventures Bring Startup & Investor Networking Event to Santa Barbara on October 8 - 112

Similar on PennZone

  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us